Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cross-licensing deal expands Amersham's market

This article was originally published in Clinica

Executive Summary

Amersham, the UK healthcare and life sciences group, announced an important cross-licensing agreement at the same time as reporting strong first-half results. The cross-licensing deal gives Amersham patent access to Roche's thermostable enzymes for sequencing, terminator chemistry (DuPont patents) and four colour process chemistry (Caltech patents) in return for patent access to Amersham's thermostable enzymes for sequencing (Harvard and Amersham patents).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT089578

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel